atrial fibrillation - prevention - patients without history of AF (primary prevention) clinical trials results meta-analysis

<h1> <a href="TM10-120-prevention-atrial fibrillation" > <strong>atrial fibrillation</strong> - prevention </a> - patients without history of AF (primary prevention) trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t9791.htm"> ARMYDA-3, 2006 </a> <br> </td> <td> atorvastatin 40mg daily<br>  <i>versus</i> <br> placebo </td> <td> patients with scheduled cardiac surgery without history of AF </td> <td> follow-up 30 days<br> n=101/99<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9792.htm"> Chello, 2006 </a> <br> </td> <td> atorvastatin 20mg daily<br>  <i>versus</i> <br> placebo </td> <td> patients with scheduled coronary bypass surgery </td> <td> follow-up 3 weeks<br> n=20/20<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9793.htm"> MIRACL, </a> <br> </td> <td> atorvastatin 80mg daily<br>  <i>versus</i> <br> placebo </td> <td> Acute coronary syndrome; subgroup without history of AF </td> <td> follow-up 16 weeks<br> n=1421/1440<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9794.htm"> TRACE, 1999 </a> <br> </td> <td> trandolapil<br>  <i>versus</i> <br> placebo </td> <td> Post–myocardial infarction </td> <td> follow-up 2.4 y<br> n=790/787<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9795.htm"> SOLVD, 2003 </a> <br> </td> <td> enalapril<br>  <i>versus</i> <br> placebo </td> <td> Heart failure </td> <td> follow-up 2.9 y<br> n=186/188<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9796.htm"> GISSI-3, 2003 </a> <br> </td> <td> lisinopril<br>  <i>versus</i> <br> placebo </td> <td> Post–myocardial infarction </td> <td> follow-up 0.5 y<br> n=8902/8846<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9797.htm"> Val-HeFT, 2003 </a> <br> </td> <td> valsartan<br>  <i>versus</i> <br> placebo </td> <td> Heart failure </td> <td> follow-up 1.92 y<br> n=2506/2494<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9798.htm"> LIFE, 2005 </a> <br> </td> <td> losartan<br>  <i>versus</i> <br> atenolol </td> <td> hypertension </td> <td> follow-up 4.8 y<br> n=4298/4182<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9799.htm"> CHARM, 2005 </a> <br> </td> <td> candesartan<br>  <i>versus</i> <br> placebo </td> <td> Heart failure </td> <td> follow-up 3.17 y<br> n=3225/3221<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9804.htm"> VA HIT, </a> <br> </td> <td> gemfibrozil<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up 4.4 y<br> n=1070/1060<br> Parallel groups<br> double blind <br> </td> </tr> </table> <h2>References</h2> <p> <b>ARMYDA-3, 2006 : </b> Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio GRandomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. <i>Circulation 2006;114:1455-61</i> [PMID 17000910] 10.1161/CIRCULATIONAHA.106.621763 </p> <p> <b>Chello, 2006 : </b> Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agrò F, Carassiti M, Covino EEffects of atorvastatin on systemic inflammatory response after coronary bypass surgery. <i>Crit Care Med 2006;34:660-7</i> [PMID 16505650] 10.1097/01.CCM.0000201407.89977.EA </p> <p> <b>MIRACL, : </b> Schwartz GG, Olsson AG, Chaitman B, Goldberger J, Szarek M, <i>Circulation 2004;110 Suppl:S740</i> [PMID ] </p> <p> <b>VA HIT, : </b> Adabag AS, Mithani S, Al Aloul B, Collins D, Bertog S, Bloomfield HEEfficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial. <i>Am Heart J 2009;157:913-8</i> [PMID 19376321] </p>